Cardiovascular risk factors are not treated to target in hypertensive patients in primary care

References

• Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–1360.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, . Reappraisal of European guidelines of hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–2159.
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, . European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1–S113.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2009. Diabetes Care. 2009;32 Suppl 1:13–61.
   PubMed Web of Science ®Google Scholar
• Lindholm, LH, Agenäs I, Carlbeg B, Dahlgren H, de Faire U, Hedblad B, . Moderately elevated blood pressure. A systematic literature review. Stockholm: The Swedish Council on Technology Assessment in Health Care. 2004. Report 170/1, 1–248 and 170/2, 1–514.
   Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, . Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363–2369.
   PubMed Web of Science ®Google Scholar
• Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52:818–827.
   PubMed Web of Science ®Google Scholar
• Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G, . High remaining risk in poorly treated hypertension: The ‘rule of halves’ still exists. J Hypertens. 2002;20:2081–2088.
   PubMed Web of Science ®Google Scholar
• Hedblad B, Nerbrand C, Ekesbo R, Johansson L, Midlöv P, Brunkstedt I, . High blood pressure despite treatment: Results from a cross-sectional primary healthcare-based study in southern Sweden. Scand J Prim Health Care. 2006; 24:224–230.
   PubMed Web of Science ®Google Scholar
• Journath G, Hellénius ML, Petersson U, Theobald H, Nilsson PM; Hyper-Q Study Group Sweden. Sex differences in risk factor control of treated hypertensives: A national primary healthcare-based study in Sweden. Eur J Cardiovasc Prev Rehabil. 2008;15:258–262.
   PubMedGoogle Scholar
• Fagard RH, van den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002;20:1297–1302.
   PubMed Web of Science ®Google Scholar
• Buckley B, Shanahan E, Colwell N, Turgonyi E, Bramlage P, Perry IJ. Blood pressure control in hypertensive patients in Irish primary care practices. J Clin Hypertens (Greenwich). 2009;11:432–440.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris, JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1245–1252.
   Google Scholar
• Ljungman C, Mortensen L, Kahan T, Manhem K. Treatment of mild to moderate hypertension by gender perspective. J Womens Health. 2009;18:1049–1062.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149–1158.
   PubMed Web of Science ®Google Scholar
• Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, . Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: An economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil. 2005;12:29–36.
   PubMed Web of Science ®Google Scholar
• Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: A systematic review. Br J Gen Pract. 2005;55:875–882.
   PubMed Web of Science ®Google Scholar
• Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, . Quality improvement strategies for hypertension management: A systematic review. Med Care. 2006;44:646–657.
   PubMed Web of Science ®Google Scholar
• Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996–2003. Diabet Med.2005;22: 1420–1426.
   PubMed Web of Science ®Google Scholar